Published: 2020-04-23

A prospective cross-sectional study to evaluate the economic burden of patients diagnosed with depression in a tertiary care hospital

D. K. Dhodi, S. R. Sinha, F. Dawer, M. S. Chavan


Background: The objective of the study was to evaluate the cost of care of depression in terms of direct and indirect costs.

Methods: 150 patients diagnosed with depression attending psychiatry OPD at Sir J.J. Group of Hospitals, Mumbai, fulfilling the inclusion criteria were explained about the study. Written informed consent were taken. Direct and Indirect costs were recorded in structured case record forms by interviewing the patients. Cost driving factors were identified.

Results: Total annual direct cost were INR 6,378.16 which included drug costs, travel expenses, physician’s consultation, cost of investigations, hospitalisation cost while total Indirect costs were INR 16,860 which included days of work both of the patient and the caretaker.

Conclusions: The indirect cost was almost thrice the direct costs. Hospitalisation cost and loss of working days due to depression was contributed the most to the direct costs and indirect costs respectively. Economic burden of depression is found out to be 16.30% of per capita gross domestic product in year 2018-19.


Depression, Economic burden, Direct and Indirect cost

Full Text:



Depression: A Global Public Health Concern. WHO; 2012.

WHO. ICD-10. International Statistical Classification of Diseases and Related Health Problems 2010 - 10th Revision. Accessed on 30 September 2018.

Vos T. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380(9859):2163-96.

Birnbaum HG. Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance. Depress Anxiety. 2010;27(1):78-89.

Gustavsson A, Svensson M, Jacobi F, Allgulander C. Alonso J, Beghi E, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21:718-79.

Fineberg NA, Haddad PM, Carpenter L, Gannon B, Sharpe R, Young AH, et al. The size, burden and cost of disorders of the brain in the UK. J Psychopharmacol. 2013;27:761-70.

Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-illness studies: a review of current methods. Pharmaco Economics. 2006;24:869-90.

Sharma P, Das SK, Deshpande SN. An estimate of the monthly cost of two major mental disorders in an Indian metropolis. Indian J Psychiatry. 2006;48:143-8.

Somaiya M, Grover S, Avasthi A, Chakrabarti S. Changes in cost of treating schizophrenia: comparison of two studies done a decade apart. Psychiatry Res. 2014;215:547-53.

Sarkar S, Mathan K, Sakey S, Shaik S, Subramanian K, Kattimani S. Cost-of-treatment of clinically stable severe mental lilnesses in India. Indian J Soc Psychiatry. 2017;33:262-8.

Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9:90.

Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe: a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol. 2005;15:357-76.

Karampampa K, Borgstrom F, Jonsson B. Economic burden of depression of society. Medicographia. 2011;33(2):163-8.

Luppa M, Heinrich S, Angermeyer MC, Konig HH, Heller RSG. Cost-ofillness studies of depression: a systematic review. J Affect Disord. 2007;98:29-43.

Sarkar S, Mathan K, Sakey S, Shaik S, Subramanian K, Kattimani S. Cost-of-treatment of clinically stable severe mental lilnesses in India. Indian J of Social Psychiatry. 2017;33(3):262.

Sobocki P, Ekman M, Agren H, Runeson B, Jonsson B. The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression. Int J Clin Pract. 2006;60:791-8.